Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Background Preclinical studies and results of a phase 2 trial of abiraterone and olaparib
suggest a combined antitumor effect when the poly (adenosine diphosphate [ADP]-ribose) …

FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Background Metastatic castration-resistant prostate cancers are enriched for DNA repair
gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP …

Background PROpel met its primary endpoint showing statistically significant improvement
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …

Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …